Founded in 1995 and headquartered in Sunnyvale, California, Intuitive Surgical (NASDAQ:ISRG) (NASDAQ: ISRG) is a global leader in robotic-assisted minimally invasive surgery. The company pioneered the da Vinci Surgical System, a robotic platform that enhances surgeons’ capabilities through high-definition 3D visualization, wristed instruments and computer-assisted precision. Since its commercial launch in 2000, the da Vinci System has been adopted by medical centers worldwide and applied to a broad range of procedures, including urology, gynecology, general surgery, thoracic and cardiothoracic interventions.
Intuitive’s product portfolio extends beyond its flagship da Vinci platform to include the Ion Endoluminal System, designed for minimally invasive biopsy in lung procedures. The company further supports its installed base with a comprehensive suite of instruments and accessories engineered for single use and multiple use, as well as software upgrades that enhance system capabilities. In addition, Intuitive offers service plans, on-site technical support and training programs for surgeons and clinical teams, aimed at optimizing clinical outcomes and operational efficiency.
Operating in more than 60 countries, Intuitive maintains a strong international presence across North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa. The company’s global infrastructure includes research and development facilities, manufacturing sites and regional training centers to support clinical adoption and post-sales services. Intuitive collaborates with healthcare institutions, key opinion leaders and medical device partners to advance robotic surgery applications and expand its therapeutic footprint.
Led by President and Chief Executive Officer Gary S. Guthart, Intuitive Surgical continues to invest in research and innovation, focusing on expanding its technology platforms and exploring new surgical domains. Through ongoing product development, regulatory approvals and clinical studies, the company aims to drive broader adoption of robotic-assisted surgery and improve patient care by enabling less invasive procedures with faster recovery times and reduced hospital stays.
